AbbVie has agreed to acquire Gilgamesh Pharmaceuticals Inc.’s lead investigational candidate, currently in clinical development for the treatment of patients with moderate-to-severe major depressive disorder (MDD), for up to $1.2 billion, inclusive of an upfront payment and development milestones. Bretisilocin, a 5-HT2A receptor agonist and 5-HT releaser, is a novel, next-generation psychedelic compound that has been shown to exert a shorter duration of psychoactive experience, while re...